Evolent Health posts Q3 2026 loss, lifts full‑year Adjusted EBITDA guidance
Evolent Health reported third‑quarter 2026 revenue of $725.4 million, a 51% year‑over‑year increase, and a net loss of $23.6 million, or $0.21 per share. Adjusted EBITDA fell to $34.3 million, and the company raised its full‑year Adjusted EBITDA outlook to $130 million‑$135 million while keeping its FY 2026 revenue guidance of $2.6 billion‑$2.7 billion. Management highlighted a four‑year renewal with its largest Surgical Management customer and new oncology and specialty‑technology contracts covering roughly 1 million commercial lives and 11 additional states.
Why it matters
The raised Adjusted EBITDA guidance suggests higher margin potential, which may support the stock’s valuation. The unchanged revenue guidance signals that investors should not expect top‑line acceleration beyond the current $2.6‑$2.7 billion range.
Key facts
- 1Revenue for the three months ended September 30 2026 was $725,367 thousand, up from $479,533 thousand in 2025. prnewswire.com
- 2Net loss attributable to common shareholders was $(23,566) thousand, compared with $(26,930) thousand in 2025. prnewswire.com
- 3Adjusted EBITDA for the quarter was $34,257 thousand, down from $38,955 thousand in 2025. prnewswire.com
- 4Full‑year Adjusted EBITDA guidance was raised to $130 million‑$135 million. prnewswire.com
- 5Full‑year revenue guidance remains $2.6 billion‑$2.7 billion. finance.yahoo.com
- 6The company announced a four‑year renewal with its largest Surgical Management customer and new oncology contracts covering approximately 1 million commercial lives, plus a specialty‑technology expansion into 11 additional states. sec.gov
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.